STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
The U.S. Food and Drug Administration approved a new breast cancer medication from Roche on Monday, paving the way for the Swiss pharmaceutical giant to launch a drug it believes could become its highest-selling ever. The FDA's approval of Wilserdly, also referred to as giredestrant, represented one of the most significant regulatory decisions the company had been eagerly anticipating.
This approval also provides Roche with additional ground in the breast cancer treatment landscape, a sector where the company has historically excelled with its Herceptin drug through its Genentech subsidiary, though it has lagged behind competitors in recent years in the realm of oncology. The FDA's approval targets patients with HR-positive, HER2-negative advanced breast cancer who have developed resistance to standard treatments due to a mutation in the ESR1 gene.
The Wilserdly trial, known as evERA, demonstrated that the oral treatment, classified as a selective estrogen receptor degrader or SERD, extends the time frame before tumors advance.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.